Amer M Beitinjaneh, MD

Dr. Amer Beitinjaneh is a Professor of Clinical Medicine at the University of Miami Miller School of Medicine and a nationally recognized hematologist-oncologist specializing in hematopoietic stem cell transplantation, CAR T-cell therapy, and complex hematologic malignancies. With more than 15 years of experience, his clinical and research work focuses on advancing novel cellular and immune-based therapies for patients with high-risk and relapsed hematologic malignancies include leukemia, lymphoma, and Multiple Myeloma.

Dr. Beitinjaneh leads the Transplantation and Cellular Therapy Site Disease Group at Sylvester Comprehensive Cancer Center and serves as the institutional Principal Investigator for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). He has led numerous investigator-initiated, federally funded, and industry-sponsored clinical trials, including first-in-human and early-phase studies. His expertise includes clinical trial design, therapeutic development, efficacy and safety evaluation, and multicenter research collaboration.

He has authored or co-authored more than 100 peer-reviewed publications and serves currently on national and international committees, including ASTCT, CIBMTR, EBMT, and BMT CTN. A Foundation for the Accreditation of Cellular Therapy (FACT) inspector for over a decade, he contributes to clinical practice standards, quality assessment, and patient safety in transplantation and cellular therapy. His expertise also encompasses evidence-based clinical decision-making and management of complex treatment-related complications.

Dr. Beitinjaneh directs the University of Miami Cellular Therapy and Stem Cell Transplantation Fellowship and serves as Site Director at Sylvester Comprehensive Cancer Center for ACGME-accredited Hematology/Oncology Fellowship programs affiliated with Broward Health North and Cleveland Clinic Florida. He has also served on the American Board of Internal Medicine (ABIM) Hematology Item-Writing Committee and contributes to ASTCT education and practice guideline initiatives.

His academic interests include novel therapeutic development, clinical trial innovation, and improving safety and outcomes in transplantation and cellular immunotherapy.